NBIX Neurocrine Biosciences, Inc.
Platform & Compounding FCF
B+ 77.9 / 100 composite

AlphaQuality composite grade, weighted for platform & compounding fcf businesses.

Profitability

Weight: 25%
B- 63
  • 5yr Avg ROIC 7.5%
  • Operating Margin Trend +3.27 pp/yr

Capital Efficiency

Weight: 15%
C- 48
  • 5yr Avg ROE 8.1%
  • 5yr Share-Count CAGR 1.2%

Growth Quality

Weight: 25%
A+ 100
  • 5yr Revenue CAGR 26.0%
  • 5yr EPS CAGR 50.1%
  • Revenue-Growth Years (5) 5/5

Cash Generation

Weight: 20%
A 88
  • 5yr FCF Margin 22.2%
  • 5yr FCF/NI Conversion 1.87x

Balance Sheet

Weight: 10%
A+ 100
  • Net Debt / EBITDA -1.60x
  • Interest Coverage (EBIT/Int) 30.00x
  • Altman Z-Score 8.07

Stability

Weight: 5%
C- 46
  • EPS Volatility (σ/μ) 0.77
  • Piotroski F-Score 5
  • Negative-Revenue Years (5) 0/5

Guru Flow

Curated superinvestor sentiment — not part of the AlphaQuality grade.
Holding

3 of 3 gurus held; 1 new buy; 1 added; 1 trimmed.

Holders
3 +1
Avg Δ position
+56.2%
New buys
1
Full exits
0
As of Q1 2026